<DOC>
	<DOCNO>NCT01099618</DOCNO>
	<brief_summary>The study intend enrol 48 subject diabetes . Diabetic subject longer need insulin randomly place ( like flip coin ) diabetes pill call metformin , diabetes pill call sitagliptin placebo pill ( pill without active medication ) . Subjects pill follow 3½ year undergo blood test specify interval assess ability make insulin . These study allow well understanding factor lead high blood sugar patient ketosis-prone diabetes mellitus ( KPDM ) direct best diabetes treatment patient population . Hypothesis : Metformin therapy sitagliptin therapy compare placebo , improve β-cell function , insulin sensitivity , allow long period time prior encounter insulin-deficient relapse discontinuation insulin therapy .</brief_summary>
	<brief_title>Ketosis-Prone Diabetes Mellitus ( KPDM ) : Metformin Versus Sitagliptin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . All newly diagnose overweight/obese ( BMI &gt; /=28 kg/m2 ) AfricanAmerican patient newonset DKA and/or severe hyperglycemia without apparent precipitating cause consider inclusion study . The diagnosis DKA establish standard criterion ( blood glucose &gt; 250 mg/dL , pH &lt; 7.3 , HCO3 &lt; 18 mmol/L , increase anion gap ) . 2 . The hyperglycemic group include patient admission plasma glucose &gt; 400 mg/dL without presence metabolic acidosis ketosis . 1. significant medical surgical illness , include limited myocardial ischemia , congestive heart failure , chronic renal insufficiency , liver failure , infectious process ; 2. recognize suspect endocrine disorder associate increased insulin resistance , hypercortisolism , acromegaly , hyperthyroidism ; 3. bleeding disorder , thrombocytopenia , abnormality coagulation study ; 4. pregnancy , 5. allergy component metformin sitagliptin .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>